Community-Acquired Pneumonia Treatment

Introduction to Community-Acquired Pneumonia

• Community-acquired pneumonia (CAP) requires prompt and effective treatment to reduce morbidity and mortality, as recommended by the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) 1

Recommended Antibiotic Regimens

• The combination of a β-lactam (such as ceftriaxone) and a macrolide (such as azithromycin) is recommended for hospitalized patients with CAP, as per the IDSA and ATS guidelines, to ensure coverage of both typical and atypical pathogens 1
• For severely ill patients admitted to the ICU, a β-lactam (ceftriaxone) plus either azithromycin or a respiratory fluoroquinolone is strongly recommended by the IDSA and ATS to cover Legionella species and other severe pneumonia-causing pathogens 1
• Macrolide monotherapy (e.g., azithromycin) is recommended as a first-line treatment option for atypical pneumonia by the American Thoracic Society and British Thoracic Society 2, 3
• The following treatment options are recommended as alternative or first-line treatments:

4

Treatment Duration and Review

• The duration of antimicrobial therapy for pneumonia varies from 5-7 days for uncomplicated cases, 7-10 days for pneumonia caused by common bacteria, and 10-14 days for pneumonia caused by atypical pathogens, depending on the causative pathogen and patient response 2, 5, 1
• The British Thoracic Society recommends a treatment duration of at least 14-21 days for Legionella pneumonia 3
• Clinical review is recommended for all patients at around 6 weeks, and chest radiograph for patients with persistent symptoms or physical signs, or those at higher risk of underlying malignancy (especially smokers and those over 50 years) 3

Patient Assessment and Management

• Daily assessment of vital signs and clinical response is essential, with patients expected to show improvement within 48-72 hours on adequate therapy, as recommended by the Infectious Diseases Society of America 6, 2, 7
• Oxygen therapy should be provided to maintain SaO2 >92%, along with adequate hydration, rest, and analgesics for pleuritic pain if needed, as recommended by the British Thoracic Society and the European Society of Clinical Microbiology and Infectious Diseases 3, 5, 4
• Pneumonia severity should be assessed using validated tools (CURB-65 or Pneumonia Severity Index), and patients should be evaluated for sepsis criteria requiring ICU admission, as recommended by the American Thoracic Society and Infectious Diseases Society of America 2, 5

Special Considerations

• COPD patients are at higher risk for drug-resistant pathogens, especially if they've had multiple antibiotic courses, and should be considered for antipseudomonal coverage if risk factors are present, as recommended by the American Thoracic Society and Infectious Diseases Society of America 8, 9
• The use of azithromycin should be avoided in patients with known QT prolongation, history of torsades de pointes, congenital long QT syndrome, uncompensated heart failure, or concurrent use of other QT-prolonging medications, as recommended by the Infectious Diseases Society of America 7, 10
• Macrolide resistance in Mycoplasma pneumoniae has been increasing worldwide, particularly in Asia, and alternative treatments such as doxycycline or respiratory fluoroquinolones may be necessary in cases of treatment failure, as recommended by the Clinical Microbiology and Infection guidelines 1, 7